

5. Department of Bacteriology II

- 1) Suzuki S, Ohnishi M, Kawanishi M, Akiba M, Kuroda M. Investigation of a plasmid genome database for colistin-resistance gene *mcr-1*. Lancet Infect Dis. 2016 Mar;16(3):284-5.
- 2) Ushizawa H, Yahata Y, Endo T, Iwashita T, Misawa M, Sonobe M, Yamagishi T, Kamiya H, Nakashima K, Matsui T, Matsui M, Suzuki S, Shibayama K, Doi M, Irie F, Yamato S, Otomo Y, Oishi K. A epidemiological investigation of a nosocomial outbreak of multidrug-resistant *Acinetobacter baumannii* in a critical care center in Japan, 2011-2012. Jpn J Infect Dis 2016, 69:143-148.
- 3) Omori R, Nakata Y, Tessmer HL, Suzuki S, Shibayama K. The determinant of periodicity in *Mycoplasma pneumoniae* incidence: an insight from mathematical modelling. Sci Rep. 2015 Sep 28;5:14473.
- 4) Suzuki M, Nishio H, Asagoe K, Kida K, Suzuki S, Matsui M, Shibayama K. Genome Sequence of a Carbapenem-Resistant Strain of *Ralstonia mannitolilytica*. Genome Announc. 2015 May 7;3(3).
- 5) Yamada R, Kimura K, Nagano N, Nagano Y, Suzuki S, Jin W, Wachino J, Yamada K, Shibayama K, Arakawa Y. Comparative Analysis of Penicillin-Susceptible and Non-Susceptible Isolates of Group B *Streptococci* by Multilocus Sequence Typing. Jpn J Infect Dis. 2015;68(4):326-9.
- 6) Nakane D, Kenri T, Matsuo L and Miyata M. Systematic Structural Analyses of Attachment Organelle in *Mycoplasma pneumoniae*. PLoS Pathog. 2015, 11 : e1005299. PMID: 26633540
- 7) Senoh M, Kato H, Fukuda T, Niikawa A, Hori Y, Hagiya H, Ito Y, Miki H, Abe Y, Furuta K, Takeuchi H, Tajima H, Tominaga H, Satomura H, Morita S, Tanada A, Hara T, Kawada M, Sato Y, Takahashi M, Higuchi A, Nakajima T, Wakamatsu Y, Toyokawa M, Ueda A, Roberts P, Miyajima F, Shibayama K. Predominance of PCR-ribotypes, 018 (smz) and 369 (trf) of *Clostridium difficile* in Japan: A potential relationship with other global circulating strains? J Med Microbiol 2015, 64:1226-1236.
- 8) Tanaka T, Kato H, Fujimoto T. Successful fecal microbiota transplantation as an initial therapy for *Clostridium difficile* infection on an outpatient basis. Internal Medicine 2016, 55:999-1000.
- 9) Senoh M, Hamabata T, Takeda Y. A factor converting viable but nonculturable *Vibrio cholerae* to a culturable state in eukaryotic cells is a human catalase. Microbiologyopen 2015, 4:589-596.
- 10) Mochizuki Y, Saeki H, Iwaki M, Takagi H, Shibayama K, Amao H, Yamamoto A. A novel experimental platform for toxigenic and nontoxigenic *Corynebacterium ulcerans* infection in mice. FEMS Pathogens and Disease 2016, 74:ftv109.
- 11) Iwaki M, Konda T. Adenylate cyclase toxin-mediated delivery of the S1 subunit of pertussis toxin into mammalian cells. FEMS Pathogens and Disease 2016, 74:ftv110.
- 12) Mottate K, Yokote H, Mori S, Horita A, Miyatsu Y, Torii Y, Kozaki S, Iwaki M, Takahashi M, Ginnaga A. Retrospective survey to evaluate the safety and efficacy of Japanese botulinum antitoxin therapy in Japan. Toxicon 2016, 110:12-18.
- 13) Katsukawa C, Komiya T, Umeda K, Goto M, Yanai T, Takahashi M, Yamamoto A, Iwaki M. Toxigenic *Corynebacterium ulcerans* isolated from a hunting dog and its diphtheria toxin antibody titer. Microbiology and Immunology 2016, 60:177-186.
- 14) Katsukawa C, Umeda K, Inamori I, Kosono Y, Tanigawa T, Komiya T, Iwaki M, Yamamoto A, Nakatsu S. Toxigenic *Corynebacterium ulcerans* isolated from a wild bird (ural owl) and its feed (shrew-moles): comparison of molecular types with human isolates. BMC Research Notes 2016, 9:181.
- 15) Murata S, Suzuki H, Sakamoto S, Miki T, Rimbara E.

- Shibayama K, Koyama S, Tamai K, Yaguchi Y, Tada M. *Helicobacter cinaedi*-associated Vertebral Osteomyelitis in an Immunocompetent Patient. Intern Med. 2015;54(24):3221-4.
- 16) Flahou B, Rimbara E, Mori S, Haesebrouck F, Shibayama K. The Other Helicobacters. Helicobacter. 2015;20 Suppl 1:62-7.
- 17) Akashi Y, Igarashi J, Suzuki H, Rimbara E, Shibayama K, Nin S, Tamai K, Yaguchi Y, Shiigai M, Oikawa T, Suzuki M. Pararenal Lymphatic Cyst Infection Caused by *Helicobacter cinaedi*. Intern Med. 2015;54(11):1437-40.
- 18) Honda N, Kim H, Rimbara E, Kato A, Shibayama K, Mori S. Purification and functional characterization of diadenosine 5',5'''-P(1),P(4)-tetraphosphate phosphorylases from *Mycobacterium smegmatis* and *Mycobacterium avium*. Protein Expr Purif. 2015;112:37-42.
- 19) Trespalacios AA, Rimbara E, Otero W, Reddy R, Graham DY. Improved allele-specific PCR assays for detection of clarithromycin and fluoroquinolone resistant of *Helicobacter pylori* in gastric biopsies: identification of N87I mutation in GyrA. Diagn Microbiol Infect Dis. 2015;81(4):251-5.
- 20) Changkwanyeun R, Usui M, Kongsoi S, Yokoyama K, Kim H, Suthienkul O, Changkaew K, Nakajima C, Tamura Y, Suzuki Y. Characterization of *Campylobacter jejuni* DNA gyrase as the target of quinolones. Journal of Infection and Chemotherapy. 2015;21(8):604-9.
- 21) Graham DY, Rimbara E. *Helicobacter pylori* infection. Clinical Infectious Disease, 2nd edition . 2015;138:907-14.
- 22) Kamachi K, Yoshino S, Katsukawa C, Otsuka N, Hiramatsu Y, Shibayama K. Laboratory-based surveillance of pertussis using multitarget real-time PCR in Japan: evidence for *Bordetella pertussis* infection in preteens and teens. New Microbes New Infect. 2015 Oct 22;8:70-4.
- 23) Hanawa T, Kamachi K, Yonezawa H, Fukutomi T, Kawakami H, Kamiya S. Glutamate limitation, BvgAS activation, and (p)ppGpp regulate the expression of the *Bordetella pertussis* type 3 secretion system. J Bacteriol. 2015 Nov 2;198(2):343-51.
- 24) Galit SR, Otsuka N, Furuse Y, Almonia DJ, Sombrero LT, Capeding RZ, Lupisan SP, Saito M, Oshitani H, Hiramatsu Y, Shibayama K, Kamachi K; Tohoku-RITM Collaborating Research Team. Molecular epidemiology of *Bordetella pertussis* in the Philippines in 2012-2014. Int J Infect Dis. 2015 Jun;35:24-6.
- 25) Torkaman MR, Kamachi K, Nikbin VS, Lotfi MN, Shahcheraghi F. Comparison of loop-mediated isothermal amplification and real-time PCR for detecting *Bordetella pertussis*. J Med Microbiol. 2015 Apr;64(Pt 4):463-5.